BITR
Biotron Limited
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
7
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Biotron Limited - Rights - Applications Close 25-Mar-2025 Deferred
π Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in BITR
7
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in BITR
N/A
BITR investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
10%
100k - 150k
50k - 100k
40%
Less than 50k
40%
πΆ Age of investors
18 - 25
14%
26 - 34
14%
35 - 90
71%
π Legal gender of investors
Female
Male
100%
Pearlers who invest in BITR also invest in...
Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is primarily engaged in the funding and management of intermediate and applied biotechnology research and development projects. The Companyβs clinical programs include BIT225-001, BIT225-003, BIT225-004, BIT225-005, BIT225-006, BIT225-007 and BIT225-008. BIT225 is in mid-stage clinical development for treatment of HIV-1 and Hepatitis C virus (HCV) infections, with seven clinical trials completed. BIT225 is a HIV-1 Vpu protein inhibitor with the aim of inhibiting virus replication in cellular reservoirs. BIT225 is a viral assembly inhibitor that targets HCV p7 protein. In addition to the development of BIT225, the Company has a portfolio of preclinical antiviral programs developing drugs targeting a range of significant established and emerging viral diseases such as Dengue, Zika and Influenza virus.
π Performance (5Yr p.a)
-19.21%
π Share price
$0.00 AUD
𧬠BIOTECHNOLOGY
A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6817.34m in AUM and 201 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.
π Performance (5Yr p.a)
6.63%
π Share price
$133.23 AUD
πΈ FINANCIALS
π¦πΊ AUSTRALIA
β³οΈ DIVERSIFIED
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
16.62%
π Share price
$138.21 AUD
π€ TECHNOLOGY
π GLOBAL
π HIGH PRICE GROWTH
β³οΈ DIVERSIFIED
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
6.06%
π Share price
$98.91 AUD
𧱠MATERIALS
πΈ FINANCIALS
β³οΈ DIVERSIFIED
π¦πΊ AUSTRALIA
ETHI.AX was created on 2017-01-05 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The fund aims to track the performance of an index (before fees and expenses) that includes a portfolio of large global stocks identified as Climate Leaders that have also passed screens to exclude companies with direct or significant exposure to fossil fuels or engaged in activities deemed inconsistent with responsible investment considerations.
π Performance (5Yr p.a)
12.61%
π Share price
$15.75 AUD
π GLOBAL
π HIGH PRICE GROWTH
β³οΈ DIVERSIFIED
π€ TECHNOLOGY
πΈ FINANCIALS
Want more shares? Try these...